• Philipp Ivanyi, Tabea Fröhlich, Viktor Grünwald, Stefanie Zschäbitz, Jens Bedke, and Christian Doehn.
• Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH); Claudia von Schilling, Comprehensive Cancer Center Hannover; Interdisciplinary Work Group Renal Cell CarcinomaI of AUO and AIO at DKG (IAGN-DKG); West German Cancer Center, Clinic for Internal Medicine and Clinic for Urology, University Hospital Essen, Essen, Germany (AöR); Department Medical Hospital VI, University Medical Center Heidelberg, National Center for Tumor Diseases, Heidelberg; Department of Urology, Klinikum Stuttgart and Stuttgart Cancer Center - Tumor Center Eva Mayr-Stihl, Stuttgart; Urologikum Lübeck.
• Dtsch Arztebl Int. 2024 Aug 23; 121 (17): 576586576-586.

BackgroundApproximately 15 000 people receive a diagnosis of renal cell carcinoma (RCC) in Germany each year; in 20-30% of cases, metastatic RCC (mRCC) is already present at the time of diagnosis. This disease in the metastatic stage is still mainly treated palliatively, yet the multimodal therapeutic landscape has changed markedly over the past 15 years, with the approval of many new treatments for patients with mRCC.MethodsThis review is based on prospective studies retrieved by a selective search in PubMed and the ASCO and ESMO databases and on the German and European oncological and urological guidelines for RCC.ResultsDrugs are the mainstay of treatment. mRCC can be treated with a combination of two immune checkpoint inhibitors (CPIs), a CPI and a tyrosine-kinase inhibitor (TKI) (evidence level IA), or a TKI as monotherapy (evidence level IIC-IC). With prognosis-based sequential drug treatment, a mean progressionfree survival of 12 to 24 months and an overall survival of approximately 50 months can be achieved from the time of initiation of first-line therapy. Aside from pharmacotherapy, the multidisciplinary tumor board should evaluate the indications for local treatments such as cytoreductive nephrectomy, metastasectomy, and radiotherapy, depending on the individual prognostic constellation and the patient's present condition.ConclusionOptimal individualized decisions require a high level of expertise and the collabo - ration of a multidisciplinary tumor board. Older prognostic parameters currently play a leading role in decision-making, while predictive parameters and molecular markers are not yet adequately validated.

26 keywords...

hide…